Literature DB >> 24718937

HMGB1 in hormone-related cancer: a potential therapeutic target.

Madhuwanti Srinivasan1, Souresh Banerjee, Allison Palmer, Guoxing Zheng, Aoshuang Chen, Maarten C Bosland, André Kajdacsy-Balla, Ramaswamy Kalyanasundaram, Gnanasekar Munirathinam.   

Abstract

High-mobility group box 1 (HMGB1) is a dynamic nuclear protein participating in transcription, chromatin remodelling, and DNA recombination and repair processes. Accumulating evidence indicates that its function now extends beyond the nucleus, notably its extracellular role in inflammation. HMGB1 is implicated as a late mediator of sepsis and is also believed to promote atherosclerosis and other inflammatory diseases such as rheumatoid arthritis and systemic lupus erythematosus. Interestingly, deregulation of HMGB1 is shown to be associated with the hallmarks of cancer development. Moreover, several clinical studies have shown that HMGB1 is a promising biomarker for a variety of cancer types. In this review, we provide novel insights into the role and mechanisms of HMGB1, in particular, to hormone-related cancers and its potential to serve as a therapeutic target.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24718937     DOI: 10.1007/s12672-014-0175-0

Source DB:  PubMed          Journal:  Horm Cancer        ISSN: 1868-8497            Impact factor:   3.869


  112 in total

Review 1.  Green tea catechin, epigallocatechin-3-gallate (EGCG): mechanisms, perspectives and clinical applications.

Authors:  Brahma N Singh; Sharmila Shankar; Rakesh K Srivastava
Journal:  Biochem Pharmacol       Date:  2011-07-30       Impact factor: 5.858

2.  TLR4-mediated skin carcinogenesis is dependent on immune and radioresistant cells.

Authors:  Deepak Mittal; Fabiana Saccheri; Emilie Vénéreau; Tobias Pusterla; Marco E Bianchi; Maria Rescigno
Journal:  EMBO J       Date:  2010-06-04       Impact factor: 11.598

3.  Receptor for advanced glycation end products (RAGE) partially mediates HMGB1-ERKs activation in clear cell renal cell carcinoma.

Authors:  Liguo Lin; Kaihua Zhong; Zhongkai Sun; Guozhong Wu; Guodong Ding
Journal:  J Cancer Res Clin Oncol       Date:  2011-09-24       Impact factor: 4.553

4.  HMGB1 and HMGB2 cell-specifically down-regulate the p53- and p73-dependent sequence-specific transactivation from the human Bax gene promoter.

Authors:  Michal Stros; Toshinori Ozaki; Alena Bacikova; Hajime Kageyama; Akira Nakagawara
Journal:  J Biol Chem       Date:  2001-12-17       Impact factor: 5.157

5.  Molecular basis for the redox control of nuclear transport of the structural chromatin protein Hmgb1.

Authors:  George Hoppe; Katherine E Talcott; Sanjoy K Bhattacharya; John W Crabb; Jonathan E Sears
Journal:  Exp Cell Res       Date:  2006-08-02       Impact factor: 3.905

6.  Liposomal Ag engrafted with peptides of sequence derived from HMGB1 induce potent Ag-specific and anti-tumour immunity.

Authors:  Abdus Faham; David Bennett; Joseph G Altin
Journal:  Vaccine       Date:  2009-08-04       Impact factor: 3.641

7.  HMGB1 interacts differentially with members of the Rel family of transcription factors.

Authors:  Alessandra Agresti; Rossella Lupo; Marco E Bianchi; Susanne Müller
Journal:  Biochem Biophys Res Commun       Date:  2003-03-07       Impact factor: 3.575

8.  High mobility group B1 protein interacts with its receptor RAGE in tumor cells but not in normal tissues.

Authors:  Jordana Todorova; Evdokia Pasheva
Journal:  Oncol Lett       Date:  2011-10-24       Impact factor: 2.967

9.  A novel role for HMGB1 in TLR9-mediated inflammatory responses to CpG-DNA.

Authors:  Stanimir Ivanov; Ana-Maria Dragoi; Xin Wang; Corrado Dallacosta; Jennifer Louten; Giovanna Musco; Giovanni Sitia; George S Yap; Yinsheng Wan; Christine A Biron; Marco E Bianchi; Haichao Wang; Wen-Ming Chu
Journal:  Blood       Date:  2007-06-04       Impact factor: 22.113

Review 10.  HMGB1: endogenous danger signaling.

Authors:  John R Klune; Rajeev Dhupar; Jon Cardinal; Timothy R Billiar; Allan Tsung
Journal:  Mol Med       Date:  2008 Jul-Aug       Impact factor: 6.354

View more
  13 in total

1.  microRNA-218 promotes gemcitabine sensitivity in human pancreatic cancer cells by regulating HMGB1 expression.

Authors:  Zhe Liu; Ruixia Du; Jin Long; Kejian Guo; Chunlin Ge; Shulong Bi; Yuanhong Xu
Journal:  Chin J Cancer Res       Date:  2015-06       Impact factor: 5.087

2.  HMGB1 attenuates TGF-β-induced epithelial-mesenchymal transition of FaDu hypopharyngeal carcinoma cells through regulation of RAGE expression.

Authors:  Yanmei Li; Ping Wang; Jia Zhao; Haonan Li; Dahai Liu; Wei Zhu
Journal:  Mol Cell Biochem       Date:  2017-03-11       Impact factor: 3.396

3.  HMGB1, TGF-β and NF-κB are associated with chronic allograft nephropathy.

Authors:  Shi-Qi Zhao; Zhen-Zhen Xue; Ling-Zhang Wang
Journal:  Exp Ther Med       Date:  2017-10-17       Impact factor: 2.447

4.  PARP1 interacts with HMGB1 and promotes its nuclear export in pathological myocardial hypertrophy.

Authors:  Qian Li; Zhuo-Ming Li; Shu-Ya Sun; Lu-Ping Wang; Pan-Xia Wang; Zhen Guo; Han-Wei Yang; Jian-Tao Ye; Jing Lu; Pei-Qing Liu
Journal:  Acta Pharmacol Sin       Date:  2018-07-20       Impact factor: 6.150

5.  microRNA-218 suppresses the proliferation, invasion and promotes apoptosis of pancreatic cancer cells by targeting HMGB1.

Authors:  Zhe Liu; Yuanhong Xu; Jin Long; Kejian Guo; Chunlin Ge; Ruixia Du
Journal:  Chin J Cancer Res       Date:  2015-06       Impact factor: 5.087

6.  HMGB1-mediated autophagy confers resistance to gemcitabine in hormone-independent prostate cancer cells.

Authors:  Yi-Xiang Zhang; Ye-Qing Yuan; Xue-Qi Zhang; Dong-Long Huang; Yu-Ying Wei; Jiang-Gen Yang
Journal:  Oncol Lett       Date:  2017-09-15       Impact factor: 2.967

7.  Expression of HMGB1/RAGE protein in renal carcinoma and its clinical significance.

Authors:  Guo-Qiang Qie; Chun-Ting Wang; Yu-Feng Chu; Rong Wang
Journal:  Int J Clin Exp Pathol       Date:  2015-06-01

Review 8.  High Mobility Group B Proteins, Their Partners, and Other Redox Sensors in Ovarian and Prostate Cancer.

Authors:  Aida Barreiro-Alonso; Mónica Lamas-Maceiras; Esther Rodríguez-Belmonte; Ángel Vizoso-Vázquez; María Quindós; M Esperanza Cerdán
Journal:  Oxid Med Cell Longev       Date:  2015-11-23       Impact factor: 6.543

9.  Geminin overexpression-dependent recruitment and crosstalk with mesenchymal stem cells enhance aggressiveness in triple negative breast cancers.

Authors:  Suryatheja Ananthula; Abhilasha Sinha; Mohamed El Gassim; Simran Batth; Gailen D Marshall; Lauren H Gardner; Yoshiko Shimizu; Wael M ElShamy
Journal:  Oncotarget       Date:  2016-04-12

10.  HMGB1 promotes cellular proliferation and invasion, suppresses cellular apoptosis in osteosarcoma.

Authors:  Qingbing Meng; Jie Zhao; Hongbing Liu; Guoyou Zhou; Wensheng Zhang; Xingli Xu; Minqian Zheng
Journal:  Tumour Biol       Date:  2014-08-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.